Product Categories
| Country: | China |
|---|---|
| Tel: | +86-13347807150 |
| Mobile: | +86-13347807150 |
| E-mail: | support@tgpeptide.com |
| QQ: | 511774137 |
| Skype: | Chat Now! |
| Address: | Room 1204, Building F, No. 22 Tiansheng Road, Jiangbei New Area, Nanjing |
|
Nanjing TGpeptide Biotechnology Co.,Ltd.("TGpeptide" hereafter), who is founded in 2019, located at Jiangbei New Material Industrial Park, is a professional enterprise enageged in researching, developing, manufacturing and sales of peptide, antibody and protein products and their technologies. TGpeptide got strong support and funded by government from the beginning when TGpeptide was founded. Dr. Wu, the founder and director of TGpeptide, was graduated from Georgia State University at 2011. Dr Wu engaged in peptide industrial research since he came back to China at 2012. Dr. Wu gained many honors during the research these years including "Progress Awards for Peptide Research and Bulk Manufacturing II", "Scarce Talent of Lanzhou" at 2013 etc.
|
|
| Product Name | MF | CAS | Details |
|---|
| Exendin (9-39) | C149H234N40O47S | 133514-43-9 | Details |
| (Glu1)-Fibrinopeptide B (human) | C66H95N19O26 | 103213-49-6 | Details |
| (Glu8.9)-Helodermin | C176H283N45O51 | 209340-47-6 | Details |
| Cyclo(-Arg-Ala-Asp-D-Phe-Cys) | C25H36N8O7S | 1055991-02-0 | Details |
| Fmoc-Ala-Ala-OH | C21H22N2O5 | 87512-31-0 | Details |
| Ac-Asp-Arg-Leu-Asp-Ser-OH | C25H42N8O12 | 153959-57-0 | Details |
| Fmoc-Pro-Phe-OH | C29H28N2O5 | 120943-07-9 | Details |
| H-Arg-Gly-Asp-OH | C12H22N6O6 | 99896-85-2 | Details |
| Cyclo(-Gly-Arg-Gly-Asp-Ser-Pro-Ala) | C25H40N10O10 | 128857-77-2 | Details |
| Eptifibatide | C35H49N11O9S2 | 188627-80-7 | Details |
| Fibronectin Fragment (1376-1380) | C24H39N11O8 | 158622-13-0 | Details |
| Fibronectin Fragment (1377-1388) | C56H97N19O20 | 162257-99-0 | Details |
| Exendin-4 (3-39) | C176H272N46O58S | 196109-31-6 | Details |
| PEG30K-Cys-AEEAc-Fibrinopeptide A (1-15) | Details |
| RGD-targeted Proapoptotic Peptide | C116H199N35O31S4 | 2243207-09-0 | Details |
| H-Gly-Arg-Gly-Asp-Ser-Pro-Lys-OH | C28H49N11O11 | 111119-28-9 | Details |
| Cyclo(-D-Tyr-Arg-Gly-Asp-Cys(carboxymethyl)-OH) | C26H36N8O11S | 143120-27-8 | Details |
| C(RGDfK(N3)) | C27H39N11O7 | 868845-09-4 | Details |
| Cyclo(-Arg-Gly-Asp-D-Phe-Lys) | C27H41N9O7 | 161552-03-0 | Details |
| Cyclo(-Arg-Gly-Asp-D-Phe-Glu) | C26H36N8O9 | 756500-22-8 | Details |
| Phenylac-Leu-Asp-Phe-D-Pro-NH2 | C28H41N5O7 | 209601-16-1 | Details |
| Integrin Binding Peptide | C42H63N15O16S | 278792-07-7 | Details |
| FITC-εAhx-Gly-Arg-Gly-Asp-Ser-Pro-OH | C49H59N11O16S | 2022956-44-9 | Details |
| Exendin-3 | C184H282N50O61S | 130357-25-4 | Details |
| (Tyr15)-Fibrinopeptide B (human) | C75H102N20O27 | 125455-56-3 | Details |
| H-Gly-Arg-Gly-Glu-Ser-Pro-OH | C23H39N9O10 | 99896-88-5 | Details |
| H-Cys-Arg-Gly-Asp-Phe-Pro-Ala-Ser-Ser-Cys-OH (Disulfide bond) | C41H61N13O15S2 | 166184-23-2 | Details |
| Galacto-RGD | C34H52N10O12 | 922175-70-0 | Details |
| Cyclo(-Arg-Gly-Asp-D-Phe-Cys) | C24H34N8O7S | 862772-11-0 | Details |
| H-Arg-Gly-Glu-OH | C13H24N6O6 | 20274-91-3 | Details |
| H-Gly-Arg-Ala-Asp-Ser-Pro-Lys-OH | C29H51N11O11 | 125455-58-5 | Details |
| Fmoc-Nle-Nle-OH | C27H34N2O5 | 251316-91-3 | Details |
| Fmoc-Gly-Phe-OH | C26H24N2O5 | 117370-45-3 | Details |
| H-Gly-Pen-Gly-Arg-Gly-Asp-Ser-Pro-Cys-Ala-OH (Disulfide bond between Pen2 and Cys9) | C35H57N13O14S2 | 126716-28-7 | Details |
| Fmoc-Gly-Pro-Hyp-OH | C27H29N3O7 | 185213-75-6 | Details |
| cyclo(RGDfK(Cya) | C38H62N10O12 | 1012051-16-9 | Details |
| H-Gly-Phe-Arg-Gly-Asp-Gly-Gln-OH | C30H45N11O11 | 148913-98-8 | Details |
| H-Lys-Gly-Glu-OH | C13H24N4O6 | 88096-12-2 | Details |
| H-Gly-Arg-Gly-Asp-Ser-Cys-OH | C20H35N9O10S | 91037-71-7 | Details |
| Fibrinogen Receptor Antagonist | C22H36N8O9S2 | 135702-36-2 | Details |
| Bifunctional Antiplatelet Agent | C53H103N25O13 | 148796-92-3 | Details |
| H-Asp-Arg-Gly-Asp-Ser-OH | C19H32N8O11 | 151997-53-4 | Details |
| H-Ser-Asp-Gly-Arg-Gly-OH | C17H30N8O9 | 108608-63-5 | Details |
| H-Arg-Gly-Asp-Ser-Pro-OH | C20H34N8O9 | 110697-44-4 | Details |
| H-Lys-Gln-Ala-Gly-Asp-Val-OH | C25H44N8O10 | 80755-87-9 | Details |
| Cyclo(RGDfK(Azido PEG4)) | 2227549-75-7 | Details |
| H-Gly-Arg-Gly-Asp-Ser-Pro-Cys-OH | C25H42N10O11S | 91575-26-7 | Details |
| Cyclo(-Arg-Ala-Asp-D-Tyr-Lys) | C28H43N9O8 | 1193347-53-3 | Details |
| Fibronectin CS-1 Fragment (1978-1985) | C38H64N8O15 | 136466-51-8 | Details |
| Fibronectin Adhesion-Promoting Peptide | C47H74N16O10 | 125720-21-0 | Details |
| RGD-4C | C42H60N14O16S4 | 332179-76-7 | Details |
| H-Arg-Gly-Glu-Ser-OH | C16H29N7O8 | 93674-97-6 | Details |
| Echistatin | C217H341N71O74S9 | 154303-05-6 | Details |
| Fibronectin CS-1 Fragment (1978-1982) | C26H45N5O10 | 150525-67-0 | Details |
| H-Gly-Arg-Gly-Asp-Ser-Pro-OH | C22H37N9O10 | 91037-75-1 | Details |
| Fmoc-Phe-Arg-OH | C30H33N5O5 | 250695-64-8 | Details |
| H-Lys-Gly-Asp-Ser-OH | C15H27N5O8 | 93674-95-4 | Details |
| H-Pro-Ser-Hyp-Gly-Asp-Trp-OH | C30H39N7O11 | 163722-91-6 | Details |
| Cyclo(-Arg-Ala-Asp-D-Phe-Lys) | C28H43N9O7 | 756500-23-9 | Details |
| YRGDS Fibronectin Fragment | C24H36N8O10 | 134282-68-1 | Details |
| H-Gly-Arg-Gly-Asp-Ser-OH | C17H30N8O9 | 96426-21-0 | Details |
| H-Gly-Arg-Gly-Asp-D-Ser-Pro-OH | C22H37N9O10 | 111844-24-7 | Details |
| Fibronectin Fragment (196-203) | C35H62N18O14S | 150525-72-7 | Details |
| H-Arg-Gly-Asp-Cys-OH | C15H27N7O7S | 109292-46-8 | Details |
| H-Arg-Gly-Asp-Ser-Pro-Ala-Ser-Ser-Lys-Pro-OH | C40H68N14O16 | 91575-25-6 | Details |
| H-Lys-Asn-Asn-Gln-Lys-Ser-Glu-Pro-Leu-Ile-Gly-Arg-Lys-Lys-Thr-OH | C74H133N25O23 | 111793-75-0 | Details |
| H-Gly-Arg-Gly-Asp-OH | C14H25N7O7 | 97461-81-9 | Details |
| Fibrinopeptide A (human) | C63H97N19O26 | 25422-31-5 | Details |
| Fmoc-Phe-Phe-OH | C33H30N2O5 | 84889-09-8 | Details |
| Cyclo(-Ala-Arg-Gly-Asp-3-aminomethylbenzoyl) | C23H32N8O7 | 153381-95-4 | Details |
| H-Gly-Arg-Gly-Asp-Asn-Pro-OH | C23H38N10O10 | 114681-65-1 | Details |
| Biotinyl-εAhx-Gly-Arg-Gly-Asp-Ser-OH | C33H55N11O12S | 2022956-45-0 | Details |
| Exendin-4 (1-8) | C35H51N11O13 | 1802078-29-0 | Details |
| (4-((2-Methylphenyl)aminocarbonyl)-aminophenyl)acetyl-Fibronectin CS-1 Fragment (1980-1983) | C36H48N6O9 | 187735-94-0 | Details |
| Fmoc-Gly-Gly-Gly-OH | C21H21N3O6 | 170941-79-4 | Details |
| (Tyr0)-Fibrinopeptide A (human) | C72H106N20O28 | 103226-11-5 | Details |
| Cyclo(-Arg-Ala-Asp-D-Phe-Val) | C27H40N8O7 | 137813-36-6 | Details |
| Fibronectin Fragment (1954-1959) | C32H63N11O7 | 184895-13-4 | Details |
| (Glu9)-Exenatide (2-39) | 196109-34-9 | Details |
| Cyclo(-Arg-Gly-Asp-D-Phe-Val) | C26H38N8O7 | 137813-35-5 | Details |
| Cyclo(-Gly-Arg-Gly-Asp-Ser-Pro) | C22H35N9O9 | 135432-37-0 | Details |
| Fmoc-Gly-Val-OH | C22H24N2O5 | 86895-14-9 | Details |
| Cilengitide | C27H40N8O7 | 188968-51-6 | Details |
| Helodermin | C176H285N47O49 | 89468-62-2 | Details |
| H-Gly-Arg-Gly-Asp-Thr-Pro-OH | C23H39N9O10 | 108682-58-2 | Details |
| Cyclo(-Arg-Gly-Asp-D-Tyr-Lys) | C27H41N9O8 | 217099-14-4 | Details |
| H-Gly-Arg-Gly-Glu-Ser-OH | C18H32N8O9 | 97461-84-2 | Details |
| Fibrinopeptide B (human) | C66H93N19O25 | 36204-23-6 | Details |
| Met(O)14-Exenatide | 1678417-38-3 | Details |
| H-Gly-Arg-Gly-Asp-Ser-NH2 | C17H31N9O8 | 143648-02-6 | Details |
| H-Arg-Gly-Asp-Ser-OH | C15H27N7O8 | 91037-65-9 | Details |
| H-D-Arg-Gly-Asp-Trp-OH | C23H32N8O7 | 144161-76-2 | Details |
| H-Cys-Gln-Asp-Ser-Glu-Thr-Arg-Thr-Phe-Tyr-OH | C52H76N14O20S | 94040-53-6 | Details |
| H-Gly-Arg-Ala-Asp-Ser-Pro-OH | C23H39N9O10 | 99896-86-3 | Details |
| Cyclo(-Gly-Arg-Gly-Glu-Ser-Pro) | C23H37N9O9 | 2022956-43-8 | Details |
| Fmoc-Phe-Ser(tBu)-OH | C31H34N2O6 | 157675-78-0 | Details |
| H-Arg-Gly-Asp-Val-OH | C17H31N7O7 | 93674-99-8 | Details |
| H-Glu[cyclo(-Arg-Gly-Asp-D-Phe-Lys)]-cyclo(-Arg-Gly-Asp-D-Phe-Lys) | C59H87N19O16 | 250612-47-6 | Details |
| H-Arg-Phe-Asp-Ser-OH | C22H33N7O8 | 102567-19-1 | Details |
| RGD Negative Control | C27H38N8O9 | 756500-24-0 | Details |
| Product Total： Product Page： | ||||
| 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 | ||||